An observational study in Aortic Aneurysm and Aortic Aneurysm Abdominal, sponsored by iVascular S.L.U.. Completed at 3 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by iVascular S.L.U. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies in Aortic Aneurysm, Abdominal with a site in France — 10 open to participants now, 13 under way, none of them phase 3. Aortic Aneurysm, Abdominal · France.
Among the 59 studies in Aortic Aneurysm, Abdominal with a site in France, this one is the 23rd largest by enrollment of the 33 observational ones that give a count, is one of 2 that started in 2026, is one of 33 observational ones, and was the 59th registered.
467 studies on the registry are indexed under Aortic Aneurysm, Abdominal; 99 are open to participants now.
Browse Aortic Aneurysm, Abdominal studies →10 of the 59 studies in Aortic Aneurysm, Abdominal with a site in France are open now. Recruiting first, the newest first:
iVascular S.L.U. · Sites in France, Belgium, Germany and 2 more countries
Ages 55+
Groupe Hospitalier de la Rochelle Ré Aunis · Sites in France
Ages 18+
University Hospital, Bordeaux · Sites in France
Ages 18+
Fondation Ophtalmologique Adolphe de Rothschild · Sites in France
Ages 50–75 · Men only · Healthy volunteers
Rijnstate Hospital · Sites in France, United States, Germany and 5 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 66 Aortic Aneurysm, Abdominal studies recruiting now, 52 (79%) set no upper age limit and 3 (5%) stop at 75 or younger; 2 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 2 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 154 is close to the median of 165 across 217 observational studies indexed under Aortic Aneurysm, Abdominal.
Median enrollment 103 across the 26 interventional studies, 181 across the 33 observational. Of the 38 that completed or were terminated, 4 (11%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 59 have an industry lead sponsor. The 10 most frequent:
iVascular S.L.U. is the lead sponsor of 14 studies on the registry; 7 are open to participants now.
iVascular S.L.U. has 2 studies filed under Aortic Aneurysm, Abdominal — fewer than ten, so there is no comparison to draw.
3 of the studies in Aortic Aneurysm, Abdominal with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05378347Medtronic CardiovascularEndurant Stent Graft System vs Excluder Endoprothesis: ADVANCE Trial | 2027-05 |
| NCT06029660Shape Memory Medical, Inc.AAA-SHAPE Pivotal Trial: Abdominal Aortic Aneurysm Sac Healing and Prevention of Expansion | 2027-07 |
| NCT05617326Fondation Ophtalmologique Adolphe de RothschildScreening for Abdominal Aortic Aneurysms in the General Practice by Ultraportable Ultrasound | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 59 studies in Aortic Aneurysm, Abdominal with a site in France, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
ReiCo is a French retrospective, multicenter, single-arm study focused on assessing the safety and clinical performance of the iCover balloon-expandable covered stent (iVascular) when implanted as a bridging stent during fEVAR for complex abdominal aortic aneurysms. The aim is to demonstrate conformity by collecting clinical evidence supporting the safe and effective use of this device in fEVAR procedures.
This retrospective clinical study evaluates the safety and performance of the iCover stent graft when used as a bridging stent in fenestrated endovascular aortic repair (fEVAR) for complex aortic aneurysms.
In fEVAR procedures, bridging stents are essential for connecting fenestrations in the aortic endograft to visceral target vessels, maintaining visceral perfusion and ensuring aneurysmal sac exclusion preventing risk of rupture and death.
The study aims to gather real-world data on iCover's clinical outcomes in this routine application, potentially supporting future conformity assessment for its extended use in fEVAR. Early studies suggest that iCover has a strong technical success, durability, and target vessel stability when repurposed as a bridging stent.
Up to date, three physician-initiated studies have assessed iCover´s performance as a bridging stent in fEVAR procedures, providing important early evidence of its performance and safety. Although 4 dedicated and approved devices for this indication have become available in the past year, variability in anatomical and procedural requirements continues to drive the evaluation of alternative technologies. This study aims to contribute important safety and performance data to inform future clinical and regulatory considerations for the iCover device in this specific indication.
467 studies on the registry are indexed under Aortic Aneurysm, Abdominal; 99 are open to participants now.
This study's enrollment of 154 is close to the median of 165 across 217 observational studies indexed under Aortic Aneurysm, Abdominal.
Browse Aortic Aneurysm, Abdominal studies →iVascular S.L.U. is the lead sponsor of 14 studies on the registry; 7 are open to participants now.
Compared within Aortic Aneurysm, Abdominal, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Aortic Aneurysm. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Selection at the primary care clinic
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Primary performance endpoint; Primary safety endpoint
iCover bridging stent patency at 12 months, defined as the proportion of iCover stents showing an absence of binary restenosis (≥ 50% stenosis) based on computed tomography angiography (CTA) and/or duplex ultrasound (DUS). Absence of iCover-related target vessel instability up to 12 months, defined as the rate of patient with an absence of target vessel instability described as a composite endpoint of any branch-related complication leading to: Aneurysm rupture/ death/ occlusion/ component separation/ or reintervention to maintain branch patency or to treat a branch-related component separation or endoleak between implantation and 12 months visit.
Time frame: 12 months
Technical success rate
Technical success rate: defined as successful introduction, deployment and appropriate positioning of the iCover bridging stent in all intended target vessels without immediate Type I or III endoleaks or conversion to open repair.
Time frame: Periprocedural
Patency
iCover bridging stent patency post-procedure and at 6-months follow-up (if available retrospectively).
Time frame: From Day 1 to ≤3 months after the index procedure, and at 6 months follow-up
Endoleaks
Freedom from iCover bridging stent related endoleaks post-procedure, at 6- (if available retrospectively), and 12- months follow-up
Time frame: From Day 1 to ≤3 months after the index procedure, at 6- (if available retrospectively, >3 to ≤9 months), and 12- months follow-up (>9 to ≤18 months)
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2026 to primary completion in Jul 2026, 4 months.
Completion moved once since we started tracking on Sep 25, 2026: Aug 2026 → Sep 2026, on Nov 6, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.